… inhibitor monotherapy. This review provides an overview of the currently available clinical
trial … on BRAF and MEK inhibitors together and in combinations with other therapeutic agents. …

… inhibitor (vemurafenib and dabrafenib) resistance. We also review the advantages of dual
therapy, including the addition of an MEK inhibitor (… compared to BRAF inhibitor monotherapy. …

… Another issue regarding MEK inhibition resides with the fact that positive patient response
is often short-lived. For example, despite combination therapy of BRAF and MEK inhibition’s …

… /ERK signaling as a mechanism of resistance to BRAF inhibitor … to combined BRAF
and MEK inhibition. Because the … MEK inhibitors can affect feedback to MEK inhibition (45–47) …

… of MEK inhibitors on immune response including the potential for combination therapy of
MEK inhibitors with immunomodulatory antibodies. Combination dabrafenib/trametinib therapy …

… MEK inhibitor combinations have been approved for use in various cancers by the US FDA.
We review the clinical data for various BRAF plus MEK combination … combination therapy …

… kinase (MAPK) kinase (MEK) inhibitors evokes unanticipated, … The effects of PARP and MEK
inhibitor combinations are … Synergistic activity of PARP and MEK inhibitor combinations in …

… Since RAF has multiple downstream pathways, combination therapy with PI3K and MEK
inhibitors may be more effective than single-agent strategies in treating RAS-mutant melanoma. …

… MAPK and PI3K/AKT/mTOR pathways has led to the rational development of targeted
therapies. Combining BRAF and MEK inhibitors to target two steps in the MAPK pathway (vertical …

… In this regard, a phase I study of combination therapy with selumetinib and the AKT inhibitor
MK-2206 has now been completed. In this trial that enrolled 51 patients, 82 one patient with …